89,314 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Marshall Wace LLP

Marshall Wace LLP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 89,314 shares of the biotechnology company’s stock, valued at approximately $426,000. Marshall Wace LLP owned 0.28% of Capricor Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CAPR. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the 1st quarter worth approximately $40,000. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares during the period. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the second quarter valued at about $147,000. Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on CAPR. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday. Oppenheimer restated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

Capricor Therapeutics Stock Down 1.0 %

Capricor Therapeutics stock opened at $17.14 on Friday. The company’s 50-day moving average price is $7.16 and its 200-day moving average price is $6.00. The company has a market cap of $548.12 million, a PE ratio of -19.70 and a beta of 4.01. Capricor Therapeutics Inc has a twelve month low of $2.68 and a twelve month high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, sell-side analysts expect that Capricor Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 12.00% of the stock is currently owned by corporate insiders.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.